Di-indenopyridines as topoisomerase II-selective anticancer agents: Design, synthesis, and structure-activity relationships.

[1]  M. Seo,et al.  Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors. , 2021, European journal of medicinal chemistry.

[2]  M. Fernandes,et al.  A Cytotoxic Bis(1,2,3‐triazol‐5‐ylidene)carbazolide Gold(III) Complex Targets DNA by Partial Intercalation , 2021, Chemistry.

[3]  J. Berger,et al.  Cell Cycle-Dependent Control and Roles of DNA Topoisomerase II , 2019, Genes.

[4]  H. Sasanuma,et al.  Type II DNA Topoisomerases Cause Spontaneous Double-Strand Breaks in Genomic DNA , 2019, Genes.

[5]  Y. Na,et al.  A chromenone analog as an ATP-competitive, DNA non-intercalative topoisomerase II catalytic inhibitor with preferences toward the alpha isoform. , 2019, Chemical communications.

[6]  T. Jeong,et al.  Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-b]pyridinol Derivatives as Potent Topoisomerase IIα-targeted Chemotherapeutic Agents for Breast Cancer. , 2019, Journal of medicinal chemistry.

[7]  M. Filipič,et al.  Structure-guided optimization of 4,6-substituted-1,3,5-triazin-2(1H)-ones as catalytic inhibitors of human DNA topoisomerase IIα. , 2019, European journal of medicinal chemistry.

[8]  N. Meanwell.  Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design. , 2018, Journal of medicinal chemistry.

[9]  H. Hiasa,et al.  Topoisomerases as anticancer targets. , 2018, The Biochemical journal.

[10]  S. Banskota,et al.  Discovery and structure-activity relationship studies of 2-benzylidene-2,3-dihydro-1H-inden-1-one and benzofuran-3(2H)-one derivatives as a novel class of potential therapeutics for inflammatory bowel disease. , 2017, European journal of medicinal chemistry.

[11]  C. Park,et al.  A novel indeno[1,2-b]pyridinone derivative, a DNA intercalative human topoisomerase IIα catalytic inhibitor, for caspase 3-independent anticancer activity. , 2017, Chemical communications.

[12]  G. Bist,et al.  Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and IIα dual inhibitors with DNA non-intercalative catalytic activity. , 2017, European journal of medicinal chemistry.

[13]  G. Chillemi,et al.  Type I DNA Topoisomerases. , 2017, Journal of medicinal chemistry.

[14]  Youngjoo Kwon,et al.  Novel 2-aryl-4-(4'-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors. , 2017, European journal of medicinal chemistry.

[15]  Y. Na,et al.  Effect of chlorine substituent on cytotoxic activities: Design and synthesis of systematically modified 2,4-diphenyl-5H-indeno[1,2-b]pyridines. , 2016, Bioorganic & medicinal chemistry letters.

[16]  A. Joubert,et al.  Antimitotic drugs in the treatment of cancer , 2015, Cancer Chemotherapy and Pharmacology.

[17]  M. D. Hill,et al.  Applications of Fluorine in Medicinal Chemistry. , 2015, Journal of medicinal chemistry.

[18]  A. Głuszyńska.  Biological potential of carbazole derivatives. , 2015, European journal of medicinal chemistry.

[19]  S. Rho,et al.  A series of novel terpyridine-skeleton molecule derivants inhibit tumor growth and metastasis by targeting topoisomerases. , 2015, Journal of medicinal chemistry.

[20]  J. T. Njardarson,et al.  Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. , 2014, Journal of medicinal chemistry.

[21]  W. Cho,et al.  Topoisomerase inhibitors as anticancer agents: a patent update , 2013, Expert opinion on therapeutic patents.

[22]  Y. Pommier.  Drugging topoisomerases: lessons and challenges. , 2013, ACS chemical biology.

[23]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[24]  A. Gomtsyan,et al.  Heterocycles in drugs and drug discovery , 2012, Chemistry of Heterocyclic Compounds.

[25]  Malgorzata N. Drwal,et al.  Exploring DNA Topoisomerase I Ligand Space in Search of Novel Anticancer Agents , 2011, PloS one.

[26]  Y. Na,et al.  Synthesis of 2,4-diaryl chromenopyridines and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship. , 2011, European journal of medicinal chemistry.

[27]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[28]  G. Nevinsky,et al.  Structure and mechanism of action of type IA DNA topoisomerases , 2009, Biochemistry (Moscow).

[29]  W. Cho,et al.  Structural modification of 3-arylisoquinolines to isoindolo[2,1-b]isoquinolinones for the development of novel topoisomerase 1 inhibitors with molecular docking study. , 2009, Bioorganic & medicinal chemistry letters.

[30]  N. Osheroff,et al.  Bimodal recognition of DNA geometry by human topoisomerase II alpha: preferential relaxation of positively supercoiled DNA requires elements in the C-terminal domain. , 2008, Biochemistry.

[31]  N. Osheroff,et al.  (-)-Epigallocatechin gallate, a major constituent of green tea, poisons human type II topoisomerases. , 2008, Chemical research in toxicology.

[32]  F. Diederich,et al.  Fluorine in Pharmaceuticals: Looking Beyond Intuition , 2007, Science.

[33]  N. Osheroff,et al.  Bioflavonoids as Poisons of Human Topoisomerase IIα and IIβ , 2007 .

[34]  Junyong Zhang,et al.  An efficient and expeditious microwave-assisted synthesis of 4-azafluorenones via a multi-component reaction , 2007 .

[35]  M. Cushman,et al.  An ab initio quantum mechanics calculation that correlates with ligand orientation and DNA cleavage site selectivity in camptothecin-DNA-topoisomerase I ternary cleavage complexes. , 2005, Journal of the American Chemical Society.

[36]  B. Hemmateenejad,et al.  Synthesis, cytotoxicity, QSAR, and intercalation study of new diindenopyridine derivatives. , 2004, Bioorganic & medicinal chemistry.

[37]  P. M. Campbell,et al.  Honokiol, a Small Molecular Weight Natural Product, Inhibits Angiogenesis in Vitro and Tumor Growth in Vivo* , 2003, Journal of Biological Chemistry.

[38]  M. Lucarini,et al.  Antioxidant activity of o-bisphenols: the role of intramolecular hydrogen bonding. , 2003, The Journal of organic chemistry.

[39]  A. J. Kaye,et al.  Ring-substituted 11-oxo-11H-indeno[1,2-b]quinoline-6-carboxamides with similar patterns of cytotoxicity to the dual topo I/II inhibitor DACA. , 1999, Bioorganic & medicinal chemistry.

[40]  J N Weinstein,et al.  Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. , 1998, Journal of medicinal chemistry.

[41]  A. Harris,et al.  Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. , 1996, British Journal of Cancer.

[42]  C. Harris,et al.  The role of the chlorine substituents in the antibiotic vancomycin: preparation and characterization of mono- and didechlorovancomycin , 1985 .

[43]  J. C. Morales,et al.  Synthesis and evaluation of new phenolic-based antioxidants: Structure–activity relationship , 2007 .